Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer

被引:46
作者
Bernstein, JL
Teraoka, S
Haile, RW
Borresen-Dale, AL
Rosenstein, BS
Gatti, RA
Diep, AT
Jansen, L
Atencio, DR
Olsen, JH
Bernstein, L
Teitelbaum, SL
Thompson, WD
Concannon, P
机构
[1] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA
[2] Virginia Mason Res Ctr, Mol Genet Program, Seattle, WA 98101 USA
[3] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[4] Norwegian Radium Hosp, Dept Genet, Oslo, Norway
[5] Mt Sinai Sch Med, Dept Radiat Oncol, New York, NY 10029 USA
[6] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA
[7] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark
[8] Univ So Maine, Dept Appl Sci Med, Portland, ME 04103 USA
关键词
atakia-telanglectasia; ATM; DHPLC mutation screening; multi-lab; quality control; breast cancer;
D O I
10.1002/humu.10206
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学]; 090102 [作物遗传育种];
摘要
Epidemiologic studies of breast and other cancers are increasingly turning toward large, multi, center designs in order to obtain adequate power to detect low-penetrance susceptibility alleles. The size of such studies often makes it necessary to distribute the genetic screening efforts to multiple sites. Careful standardization of screening methodology and quality control across sites is required for such multi-center screening designs to be efficient. In this report, we illustrate our approach to these challenges in the context of the WECARE (Women's Environment, Cancer and Radiation Epidemiology) Study, a multi-center population,based genetic epidemiologic study of women with unilateral and bilateral breast cancer. We provide optimized conditions for screening the ataxia, telangiectasia gene (ATM) for variation by denaturing high-performance liquid chromatography (DHPLC) and describe the results of two independent quality control studies at four international
引用
收藏
页码:542 / 550
页数:9
相关论文
共 40 条
[1]
The ATM gene and breast cancer:: is it really a risk factor? [J].
Angèle, S ;
Hall, J .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2000, 462 (2-3) :167-178
[2]
BODER E, 1985, ATAXIA TELANGIECTASI, P1
[3]
BREAST-CANCER AND OTHER CANCERS IN NORWEGIAN FAMILIES WITH ATAXIA-TELANGIECTASIA [J].
BORRESEN, AL ;
ANDERSEN, TI ;
TRETLI, S ;
HEIBERG, A ;
MOLLER, P .
GENES CHROMOSOMES & CANCER, 1990, 2 (04) :339-340
[4]
Castellví-Bel S, 1999, HUM MUTAT, V14, P156, DOI 10.1002/(SICI)1098-1004(1999)14:2<156::AID-HUMU7>3.0.CO
[5]
2-E
[6]
Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205
[7]
Reliability of DHPLC in mutational screening of β-globin (HBB) alleles [J].
Colosimo, A ;
Guida, V ;
De Luca, A ;
Cappabianca, MP ;
Bianco, I ;
Palka, G ;
Dallapiccola, B .
HUMAN MUTATION, 2002, 19 (03) :287-295
[8]
Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks [J].
Cortez, D ;
Wang, Y ;
Qin, J ;
Elledge, SJ .
SCIENCE, 1999, 286 (5442) :1162-1166
[9]
Dörk T, 2001, CANCER RES, V61, P7608
[10]
CANCER RISKS IN A-T HETEROZYGOTES [J].
EASTON, DF .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1994, 66 (06) :S177-S182